Lin Chih-Lung, Kwan Aij-Lie, Dumont Aaron S, Su Yu-Feng, Kassell Neal F, Wang Chih-Jen, Wu Shu-Chuan, Kuo Ching-Ling, Huang Ching-Shan, Jeng Arco Y, Liu Chin-San
Department of Neurosurgery, Kaohsiung Medical University, Kaohsiung, Taiwan.
J Neurosurg. 2007 Mar;106(3):442-8. doi: 10.3171/jns.2007.106.3.442.
Adhesion molecules, including intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin, are important mediators of inflammation, and their levels are elevated in the serum of patients following aneurysmal subarachnoid hemorrhage (SAH). The investigators previously found that CGS 26303 is effective in preventing and reversing arterial narrowing in a rabbit model of SAH. The purpose of the present study was to examine whether levels of adhesion molecules are altered after treatment with CGS 26303 in this animal model.
New Zealand White rabbits were each injected with 3 ml of autologous blood in the cisterna magna, and intravenous treatment with CGS 26303 (30 mg/kg) was initiated 1 hour later. The compound was subsequently administered at 12, 24, and 36 hours post-SAH. Blood samples were collected at 48 hours post-SAH to measure ICAM-1, VCAM-1, and E-selectin levels. After the rabbits had been killed by perfusion-fixation, the basilar arteries (BAs) were removed and sliced, and their cross-sectional areas were measured. Treatment with CGS 26303 attenuated arterial narrowing after SAH. Morphologically, corrugation of the internal elastic lamina of BAs was prominently observed in the SAH only and vehicle-treated SAH groups, but not in the CGS 26303-treated SAH group or in healthy controls. There were no significant differences in the levels of VCAM-1 among the four groups. The levels of E-selectin were increased in all animals subjected to SAH (those in the SAH only, SAH plus vehicle, and SAH plus CGS 26303 groups) compared with healthy controls (no SAH); however, the levels of ICAM-1 in the SAH only and SAH plus vehicle groups were significantly elevated (p < 0.001), and treatment with CGS 26303 reduced ICAM-1 to control levels following SAH.
These results show that ICAM-1 may play a role in mediating SAH-induced vasospasm and that a reduction of ICAM-1 levels after SAH may partly contribute to the antispastic effect of CGS 26303.
黏附分子,包括细胞间黏附分子-1(ICAM-1)、血管细胞黏附分子-1(VCAM-1)和E-选择素,是炎症的重要介质,在动脉瘤性蛛网膜下腔出血(SAH)患者的血清中其水平会升高。研究人员先前发现CGS 26303在SAH兔模型中可有效预防和逆转动脉狭窄。本研究的目的是在该动物模型中检测用CGS 26303治疗后黏附分子水平是否发生改变。
给新西兰白兔在小脑延髓池各注射3 ml自体血,1小时后开始静脉注射CGS 26303(30 mg/kg)。在SAH后12、24和36小时随后给予该化合物。在SAH后48小时采集血样以测量ICAM-1、VCAM-1和E-选择素水平。在兔经灌注固定处死之后,取出基底动脉(BA)并切片,测量其横截面积。用CGS 26303治疗可减轻SAH后的动脉狭窄。在形态学上,仅在SAH组和给予赋形剂治疗的SAH组中显著观察到BA内弹性膜的波纹,而在给予CGS 26303治疗的SAH组或健康对照组中未观察到。四组之间VCAM-1水平无显著差异。与健康对照组(无SAH)相比,所有SAH动物(仅SAH组、SAH加赋形剂组和SAH加CGS 26303组)的E-选择素水平均升高;然而,仅SAH组和SAH加赋形剂组的ICAM-1水平显著升高(p < 0.001),并且用CGS 26303治疗可使SAH后的ICAM-1水平降至对照水平。
这些结果表明ICAM-1可能在介导SAH诱导的血管痉挛中起作用,并且SAH后ICAM-1水平的降低可能部分有助于CGS 26303的抗痉挛作用。